Dutasteride is an off-label prescription option for male pattern hair loss. It may help when a clinician finds another DHT-blocking treatment appropriate, but stronger hormone suppression is not a guarantee of better results for an individual.
Finasteride inhibits type II 5-alpha reductase; dutasteride inhibits types I and II. The often-quoted roughly 70% versus 90% DHT reductions describe blood measurements, not equivalent scalp measurements. Dutasteride remains in the body much longer. A 24-week trial favored dutasteride 0.5 mg over finasteride 1 mg on hair outcomes, but cannot settle long-term comparative safety.
Dutasteride is FDA-approved for BPH, not hair loss. A clinician may prescribe it off-label for hair loss after an individual benefit-risk discussion. Research support is not the same as FDA approval for this use.
A commonly studied off-label hair-loss dose is 0.5 mg once daily, with or without food. Swallow the capsule whole; do not open or chew it. Take it only as prescribed, without doubling a missed dose or changing the schedule yourself.
Sexual symptoms and breast changes are recognized adverse effects. Effects on semen measures have been observed; the impact on an individual's fertility is unknown. Drug can remain detectable for four to six months after stopping, so symptoms do not necessarily disappear quickly. The label also covers liver disease, interactions with strong CYP3A4 inhibitors and prostate monitoring.
$45 online visit, with no required subscription. Medication is paid separately at your chosen pharmacy and depends on the prescribed drug, quantity and pharmacy quote. The clinician decides whether dutasteride or a combination is appropriate.
Dutasteride lowers PSA by about 50% within three to six months in its BPH studies. The clinician interpreting a PSA should know about current and past use; a confirmed rise from the lowest level needs evaluation. The label also warns about increased high-grade prostate-cancer findings in prevention trials. Dutasteride is not approved to prevent prostate cancer.
Do not donate blood while taking dutasteride or for at least six months after the last dose. People who are or could be pregnant should not handle the capsules; wash immediately with soap and water after contact with a leaking capsule. Seek medical advice about the exposure.
Report new mood or sexual symptoms and breast lumps, pain or nipple discharge promptly. For a severe allergic reaction with throat swelling or breathing difficulty, stop the medicine and call 911.
Sexual adverse effects may persist after dutasteride is stopped; the label says dutasteride’s role in that persistence is unknown. Report ongoing symptoms rather than assuming they will resolve when the medicine clears. Dutasteride label.
These sources support the medication facts and research discussed above. Study results apply to the doses and populations tested; they do not guarantee an individual outcome.
Other pages worth reading: